Advanced search
Publication Cover
Journal of Environmental Science and Health, Part C
Environmental Carcinogenesis and Ecotoxicology Reviews
Volume 30, 2012 - Issue 4
Submit an article Journal homepage
458
Views
40
CrossRef citations to date
0
Altmetric
Original Articles

Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies

CHIN-HSIAO TSENG Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
&
FARN-HSUAN TSENG Dana and David Dornsife College of Letters, Arts and Sciences, Department of Biological Sciences, University of Southern California, USA
Pages 368-402 | Published online: 20 Nov 2012

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Chin-Hsiao Tseng. (2022) Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 285-295.
Read now
Melissa A. Davidson, Donald R. Mattison, Laurent Azoulay & Daniel Krewski. (2018) Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Critical Reviews in Toxicology 48:1, pages 52-108.
Read now
Jinjun Ye, Li Yin, Peng Xie, Jianfeng Wu, Jian Huang, Guoren Zhou, Hanzi Xu, Emei Lu & Xia He. (2015) Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro. OncoTargets and Therapy 8, pages 1211-1218.
Read now
Awadhesh Kumar Singh. (2015) Polemics of pioglitazone: an appraisal in 2015. Expert Review of Endocrinology & Metabolism 10:4, pages 447-458.
Read now
Anna R Carta & Tanya Simuni. (2015) Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease. Expert Opinion on Investigational Drugs 24:2, pages 219-227.
Read now
Chin-Hsiao Tseng, Kuo-Yang Lee & Farn-Hsuan Tseng. (2015) An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C 33:1, pages 67-124.
Read now
Chin-Hsiao Tseng. (2014) A Review on Thiazolidinediones and Bladder Cancer in Human Studies. Journal of Environmental Science and Health, Part C 32:1, pages 1-45.
Read now
Chin-Hsiao Tseng. (2013) Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes. Annals of Medicine 45:8, pages 539-544.
Read now

Articles from other publishers (32)

Chin-Hsiao Tseng. (2023) Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan. Cancers 15:17, pages 4276.
Crossref
Chin-Hsiao Tseng. (2023) Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients. Pharmaceuticals 16:5, pages 679.
Crossref
Chin-Hsiao Tseng. (2022) Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. BMC Cancer 22:1.
Crossref
Georgios S. Papaetis. (2022) Pioglitazone, Bladder Cancer, and the Presumption of Innocence. Current Drug Safety 17:4, pages 294-318.
Crossref
Jaehyun Bae, Taegyun Park, Hyeyoung Kim, Minyoung Lee & Bong-Soo Cha. (2021) Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 45:3, pages 326-336.
Crossref
Pitchai Balakumar, Nanjaian Mahadevan & Ramanathan Sambathkumar. (2019) A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia. Current Molecular Pharmacology 12:3, pages 195-201.
Crossref
Xiao-Ping Liu, Xiao-Hong Yin, Xiang-Yu Meng, Xin-Hui Yan, Yue Cao, Xian-Tao Zeng & Xing-Huan Wang. (2018) DHCR24 predicts poor clinicopathological features of patients with bladder cancer. Medicine 97:39, pages e11830.
Crossref
Alexandre Vallée, Yves Lecarpentier, Rémy Guillevin & Jean-Noël Vallée. (2018) Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. Neuroscience Bulletin 34:3, pages 573-588.
Crossref
Elizabeth McInnes. 2017. Pathology of Taxicologists. Pathology of Taxicologists 72 111 .
Chin-Hsiao Tseng. (2016) Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. Oncotarget 8:12, pages 19057-19064.
Crossref
Chin-Hsiao Tseng. (2016) Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus. Oncotarget 8:2, pages 3042-3048.
Crossref
Julia Naidenow, Igor Hrgovic, Monika Doll, Tsige Hailemariam-Jahn, Victoria Lang, Johannes Kleemann, Stefan Kippenberger, Roland Kaufmann, Nadja Zöller & Markus Meissner. (2016) Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells. Journal of Inflammation 13:1.
Crossref
Jee Won Hwang, Hyewon Cho, Jae Yeon Lee, Youngsic Jeon, Su-Nam Kim, Sang Jin Lee, Gyu-Un Bae, Sungpil Yoon, Raok Jeon & Yong Kee Kim. (2016) The synthetic ajoene analog SPA3015 induces apoptotic cell death through crosstalk between NF-κB and PPARγ in multidrug-resistant cancer cells. Food and Chemical Toxicology 96, pages 35-42.
Crossref
YOUHONG DONG & ANPING WANG. (2016) Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study. Oncology Letters 12:1, pages 89-92.
Crossref
Chin-Hsiao Tseng. (2015) Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese. BMC Cancer 15:1.
Crossref
Tatsuo Motoki, Hirotsugu Kurobe, Yoichiro Hirata, Taisuke Nakayama, Hajime Kinoshita, Kevin A. Rocco, Hitoshi Sogabe, Takaki Hori, Masataka Sata & Tetsuya Kitagawa. (2015) PPAR-γ agonist attenuates inflammation in aortic aneurysm patients. General Thoracic and Cardiovascular Surgery 63:10, pages 565-571.
Crossref
Agata Ptaszynska, Samuel M. Cohen, Edward M. Messing, Timothy P. Reilly, Eva Johnsson & Kristina Johnsson. (2015) Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’. Diabetes Therapy 6:3, pages 357-375.
Crossref
D. Lecca, D.K. Nevin, G. Mulas, M.A. Casu, A. Diana, D. Rossi, G. Sacchetti & A.R. Carta. (2015) Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPAR? agonist in vitro and in MPTP-treated mice. Neuroscience 302, pages 23-35.
Crossref
Lorrene A. Buckley, Beatriz Silva-Lima & Mark A. Tirmenstein. 2015. Genotoxicity and Carcinogenicity Testing of Pharmaceuticals. Genotoxicity and Carcinogenicity Testing of Pharmaceuticals 183 203 .
Chin-Hsiao Tseng. (2014) Metformin Reduces Thyroid Cancer Risk in Taiwanese Patients with Type 2 Diabetes. PLoS ONE 9:10, pages e109852.
Crossref
Raymond E. Soccio, Eric R. Chen & Mitchell A. Lazar. (2014) Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes. Cell Metabolism 20:4, pages 573-591.
Crossref
Chin-Hsiao Tseng. (2014) Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes 台湾2型糖尿病患者使用吡格列酮与甲状腺癌风险. Journal of Diabetes 6:5, pages 448-450.
Crossref
Chin-Hsiao Tseng. (2014) Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes. Metabolism 63:8, pages 1049-1055.
Crossref
Simon C. BakerSaqib ShabirJennifer Southgate. (2014) Biomimetic Urothelial Tissue Models for the in Vitro Evaluation of Barrier Physiology and Bladder Drug Efficacy . Molecular Pharmaceutics 11:7, pages 1964-1970.
Crossref
Chin-Hsiao Tseng. (2014) Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. Acta Diabetologica 51:2, pages 295-303.
Crossref
Hayley Patricia Ellis & Kathreena Mary Kurian. (2014) Biological Rationale for the Use of PPARγ Agonists in Glioblastoma. Frontiers in Oncology 4.
Crossref
Chin-Hsiao Tseng. (2014) Human Insulin Does Not Increase Bladder Cancer Risk. PLoS ONE 9:1, pages e86517.
Crossref
Chin-Hsiao Tseng. (2013) Insulin Use and Smoking Jointly Increase the Risk of Bladder Cancer Mortality in Patients With Type 2 Diabetes. Clinical Genitourinary Cancer 11:4, pages 508-514.
Crossref
Chin-Hsiao Tseng. (2013) Diabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan. Acta Diabetologica 50:6, pages 879-886.
Crossref
Chin-Hsiao Tseng. (2013) Pioglitazone does not affect the risk of ovarian cancer: Analysis of a nationwide reimbursement database in Taiwan. Gynecologic Oncology 131:1, pages 135-139.
Crossref
Jean-Luc Faillie, Pierre Petit, Jean-Louis Montastruc & Dominique Hillaire-Buys. (2013) Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?. Drug Safety 36:9, pages 693-707.
Crossref
Chin-Hsiao Tseng. (2013) Rosiglitazone is not associated with an increased risk of bladder cancer. Cancer Epidemiology 37:4, pages 385-389.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.